论文部分内容阅读
[目的]观察靶动脉灌注维拉帕米和化疗药物对晚期非小细胞肺癌(NSCLC)的疗效和不良反应。[方法]对入组的51例NSCLC患者,经靶动脉灌注维拉帕米和化疗药物,每月介入治疗1个疗程,每例治疗2~4个疗程后,评估近期疗效;并采用Kaplan-Meier法,对51例中随访时间≥3年的38例患者统计生存率。[结果]51例晚期NSCLC患者中,完全缓解(CR)5例(9.80%),部分缓解(PR)36例(70.59%),总有效率(CR+PR)为80.39%;38例晚期NSCLC患者中,中位生存时间为24个月,1、2、3年生存率分别为76.3%、55.3%和26.3%;其中22例鳞癌中位无进展生存时间为17个月,13例腺癌中位无进展生存时间为10个月。15例患者(31.37%)出现白细胞下降,12例(23.53%)出现Ⅰ~Ⅱ级消化道不良反应,均未见维拉帕米相关的心血管副作用。[结论]靶动脉灌注维拉帕米联合化疗药物对于晚期NSCLC患者近、远期疗效确切,使其降期降级获得进一步治疗机会,且无明显不良反应。
[Objective] To observe the efficacy and adverse reactions of target arterial infusion of verapamil and chemotherapy drugs in advanced non-small cell lung cancer (NSCLC). Methods Fifty-one patients with NSCLC were enrolled in this study. The target arteries were infused with verapamil and chemotherapeutic drugs. One month of interventional therapy and two to four cycles of treatment were used to evaluate the short-term efficacy. Kaplan- Meier method, 51 patients in the follow-up time ≥ 3 years 38 patients survival rate. [Results] Among 51 patients with advanced NSCLC, complete remission (CR) in 5 cases (9.80%), partial remission (PR) in 36 cases (70.59%) and total effective rate (CR + PR) The median survival time was 24 months, and the 1, 2, 3-year survival rates were 76.3%, 55.3% and 26.3% respectively. The median progression-free survival time of 22 patients with squamous cell carcinoma was 17 months and 13 The median progression-free survival time was 10 months. Fifteen patients (31.37%) had leukopenia and 12 (23.53%) had grade Ⅰ ~ Ⅱ gastrointestinal adverse reactions. None of the patients had verapamil-related cardiovascular side effects. [Conclusion] The targeted arterial infusion of verapamil combined with chemotherapeutic drugs has definite and long-term curative effect in patients with advanced NSCLC. It is possible to further treat the patients with advanced NSCLC without any adverse reactions.